Neuphoria Therapeutics Inc. Overview
NEUP market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 3.00
- H
- 3.03
- L
- 3.00
- C
- 3.00
- Vol
- 504.00
Daily history from Dec 16, 2021
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $3.00
- Previous Close
- $3.03
- Day High
- $3.03
- Day Low
- $3.00
- 52 Week High
- $5.47
- 52 Week Low
- $3.00
- 7 Day Return
- -10.98%
- 30 Day Return
- -13.29%
- 90 Day Return
- -24.62%
- 1 Year Return
- -29.25%
- Daily Notional Volume
- $1.5K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.78 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -417.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.99 – $5.53 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $16.2M · P/B 0.70 · P/S 13.78.